South Korean AI firm Lunit has tied up with its investor, Guardant Well being, for AI integration.
Underneath the partnership, Lunit will combine its PD-L1 scoring algorithm into Guardant’s most cancers biomarker detection workflow within the Guardant360 TissueNextTM PD-L1 take a look at for non-small cell lung most cancers (NSCLC).
Lunit SCOPE PD-L1, a CE-marked AI answer, detects and analyses PD-L1, a sort of most cancers biomarker.
WHY IT MATTERS
The Lunit SCOPE PD-L1 does AI-based quantification of tissue samples utilizing a scoring system. Integrating it with the Guardant take a look at will improve biomarker evaluation for NSCLC sufferers, the corporate claimed in a press assertion. The AI has helped carry the take a look at’s detection of PD-L1 by over 20% in comparison with guide pathologist interpretation.
THE LARGER TREND
In 2021, Guardant Well being backed Lunit’s Collection C Tranche B funding spherical with a $26 million investment. The corporate beforehand mentioned that it expects its funding within the firm for use in growing new precision oncology merchandise that enhance most cancers care.
On Thursday, Guardant Well being formally launched Guardant Galaxy, its suite of analytical applied sciences developed internally and thru exterior partnerships. The Guardant360 TissueNext PD-L1 take a look at built-in with Lunit SCOPE PD-L1 is the primary software on this line.
In different associated information, Lunit opened the brand new yr with a three-year deal to produce its AI chest x-ray picture evaluation software program, Lunit INSIGHT CXR, to Hospital Israelita Albert Einstein, one of many greatest hospitals in Brazil.
ON THE RECORD
“The digital pathology answer from Lunit has already demonstrated the ability of AI to assist enhance [the] detection of PD-L1 in sure circumstances of NSCLC. We imagine it has the potential to contribute far more broadly to advances in figuring out most cancers biomarkers and informing therapy choices,” Guardant Well being co-CEO Helmy Eltoukhy mentioned about Lunit’s AI answer.
“The event of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 take a look at is a superb instance of utilizing superior medical picture analytics to boost precision diagnostics in lung most cancers and assist medical doctors discover the correct therapy for the correct sufferers,” Lunit CEO Brandon Suh additionally commented.
